EGFR and non-small cell lung carcinoma: RELAY is a randomised, double-blind, placebo-controlled, phase 3 trial that compared erlotinib plus ramucirumab with erlotinib monotherapy in patients suffering from untreated common-EGFR-mutated advanced NSCLC and no CNS metastases.